NorthWest Biotherapeutics Inc (NWBO)

[cybermich]

As a relatively new investor... please correct me if I am wrong..
I just watched one of the recent CEO presentations.. and if you look at 3 year survival rates.. (unless I heard wrong).. the CEO stated that seeing more than 5 percent of patients surviving past 3 years was rare.. (historically)
with most of the patients in the NWBO trial receiving the vaccine (due to the crossover design) regardless of the debate over any other issue of trial design.. bottom line.. 28 percent of patients in the trial survived more than 3 years?.. with many of those surviving much longer than 3 years..
in addition.. using a certain biomarker.. if those subjects are isolated the long term survival (more than 3 years) is about 50 percent..
again, seems to me to be much, much higher than just the SOC.

In the presentation I watched.. the CEO was upfront about the challenges of trial design for immunotherapies.. including pseudo progressions (where the tumor grows more before it improves)

I guess a moral/ethical question would be..
even if there are questions about the trial design.. would the FDA IGNORE the fact that more people are surviving using this therapy?

If NWBO's therapy is not approved.. what will be the alternative for these patients?

Logically (hopefully it applies here).. that is why intelligent folks are officially changing the endpoints.. so that this common sense can be applied to the results of the trial.